Celsense - Board of Directors



Board of Directors

Paul Kornblith, M.D., Chairman of the Board of Directors. Dr. Kornblith is a neurosurgeon, academic, inventor, and entrepreneur. He trained at Temple University, Jefferson Medical College, the University of Pennsylvania, and Massachusetts General Hospital. He was formerly a faculty member at Harvard University, Chief of Surgical Neurology at the NIH, Professor of Neurosurgery and Chairman at Albert Einstein College of Medicine, and Professor of Neurosurgery and Vice Chairman at the University of Pittsburgh. While at NIH his work led to the development of innovative chemosensitivity assays, and he also served as leader of the NIH PET program, discovering its value in clinical cancer management. In 1995, he founded and served as President and CEO of Precision Therapeutics, Inc., a cancer chemoresponse company. Presently, Dr. Kornblith is Adjunct Professor at the University of Pittsburgh School of Health and Rehabilitation Sciences. He is Western Pennsylvania Regional Director for PABiotech.

Jeffrey S. Friedman, M.D., Ph.D., is the Managing Partner of Friedman Bioventures, a San Diego-based family investment vehicle, and Chair of the Life Science Committee of the San Diego Chapter of Tech Coast Angels, one of the largest Angel Investing organization in the world. Dr. Friedman also serves as Director and Chair of the Research Committee of CurePSP, a nationwide foundation funding research and providing education and support to patients with Progressive Supranuclear Palsy (PSP) and to their families and caregivers. Dr. Friedman previously served on the Boards of Cypher Genomics and Pediatric Biosciences. After receiving his BS in Biology at MIT, Dr. Friedman earned his M.D. and Ph.D. in Cancer Biology at Stanford University. He trained in Pediatrics at Boston Children’s Hospital and Pediatric Hematology/Oncology at the Dana Farber Cancer Institute. Dr. Friedman served as an Assistant Professor and Principal Investigator at the Scripps Research Institute in La Jolla, California from 2003 until 2012.

Daniel P. Gallagher, Jr., is a partner with the Pittsburgh office of Meyer, Unkovic & Scott, LLP. Mr. Gallagher’s legal practice is currently devoted to a wide variety of financial and international business, investment and joint venture transactions. Mr. Gallagher received his J.D. from the University of Chicago and his B.A. with Honors from Yale University.

Gregory T. Hebrank, M.D. Dr. Hebrank is a co-founder and executive vice president of corporate operations and finance of Knopp Biosciences, LLC. He is also a member of the Board of Directors of LaunchCyte, LLC and a successful investor in both public and private biotechnology companies. Dr. Hebrank continues to practice medicine part time in Greensburg, Pennsylvania. He earned a B.S. in Biomedical Engineering from Vanderbilt University, an M.D. from Tulane University School of Medicine, and completed his residency training in Obstetrics and Gynecology at Magee-Women’s Hospital in Pittsburgh. Dr. Hebrank received his M.B.A. from Carnegie Mellon University.

Charles F. O’Hanlon, President and CEO. Mr. O’Hanlon was previously a Managing Director of Cornerstone Capital Advisors, of Pittsburgh, PA, where he provided financial and operating advice, interim management, and corporate finance services to privately held businesses. While at Cornerstone, he was involved in the founding of numerous new ventures, spin-offs, and re-starts of distressed companies. Prior to joining Cornerstone in 2001, he held a number of executive management positions with National City and Mellon Bank. Mr. O’Hanlon serves on the boards of several private companies. He previously served on the boards of the Pittsburgh Technology Council, the CEO Venture Fund, and the Pittsburgh Regional Healthcare Initiative. He received a B.S. in industrial management from Georgia Institute of Technology and an MBA from Robert Morris College in 1980.

Thomas Petzinger, Jr. Mr. Petzinger is also the CEO of LaunchCyte LLC, and serves as Executive VP of Business Development and Public Affairs for Knopp Neurosciences, Inc. He has formed five other life sciences ventures. He spent 22 years at The Wall Street Journal, where he served as Washington Economics Editor, deputy Washington Bureau Chief, Millennium Editor, and weekly columnist. A Pulitzer nominee for numerous investigative stories, he has also written three best-selling business books. He is a director of PABiotech. He received his B.S. in Journalism from Northwestern University, where he was a Richter International Scholar.

L. Gerald Tarantino, J.D., is a retired executive and private investor. Mr. Tarantino began his career as a Wall Street securities lawyer. For the past twenty-five years he has been the owner/manager of a range of small and medium sized businesses, both private and public, in diverse areas and industries, including sophisticated software, information technology, biotechnology, and the internet. He holds a B.A. and an LLB from the University of Pennsylvania.